HARROW, INC. Goodwill & Intangibles Disclosure
NOTE 11. INTANGIBLE ASSETS AND GOODWILL
The Company’s intangible assets at December 31, 2025 consisted of the following:
| Weighted-average | Accumulated | Net | ||||||||||||
| useful life (in years) | Cost | amortization | Carrying value | |||||||||||
| Patents | 19 | $ | 228,000 | $ | (66,000 | ) | $ | 162,000 | ||||||
| Licenses | 20 | 50,000 | (39,000 | ) | 11,000 | |||||||||
| Trademarks | Indefinite | 328,000 | 328,000 | |||||||||||
| Acquired product rights | 14 | 214,482,000 | (39,921,000 | ) | 174,561,000 | |||||||||
| Customer relationships | 7 | 190,000 | (149,000 | ) | 41,000 | |||||||||
| Trade name | 5 | 70,000 | (3,000 | ) | 67,000 | |||||||||
| State pharmacy licenses | 25 | 8,000 | (4,000 | ) | 4,000 | |||||||||
| $ | 215,356,000 | $ | (40,182,000 | ) | $ | 175,174,000 | ||||||||
The Company’s intangible assets at December 31, 2024 consisted of the following:
| Weighted-average | Net | |||||||||||||||||
| useful life | Accumulated | Carrying | ||||||||||||||||
| (in years) | Cost | amortization | Impairment | value | ||||||||||||||
| Patents | 19 | $ | 611,000 | $ | (216,000 | ) | $ | (253,000 | ) | $ | 142,000 | |||||||
| Licenses | 20 | 50,000 | (36,000 | ) | 14,000 | |||||||||||||
| Trademarks | Indefinite | 230,000 | 230,000 | |||||||||||||||
| Acquired product rights | 14 | 207,398,000 | (22,962,000 | ) | 184,436,000 | |||||||||||||
| Customer relationships | 7 | 596,000 | (542,000 | ) | 54,000 | |||||||||||||
| Trade name | 5 | 75,000 | (7,000 | ) | 68,000 | |||||||||||||
| Non-competition clause | 4 | 50,000 | (50,000 | ) | ||||||||||||||
| State pharmacy licenses | 25 | 8,000 | (3,000 | ) | 5,000 | |||||||||||||
| $ | 209,018,000 | $ | (23,816,000 | ) | $ | (253,000 | ) | $ | 184,949,000 | |||||||||
During the years ended December 31, 2025, 2024 and 2023, the Company recorded a charge of $0, $253,000 and $380,000, respectively, related to the impairment of certain licenses, trademarks, patents and patent applications. The Company determined that the sum of the expected undiscounted cash flows attributable to these intangible assets was less than their carrying value and that an impairment charge was required. Accordingly, the Company calculated the estimated fair value of the intangible assets based on the present value of the expected cash flows over their estimated lives. The impairment amount was calculated by deducting the present value of the expected cash flows from the carrying value. Significant estimates and assumptions used by the Company included sales and expense growth rates, and discounted projected cash flows. The estimates and assumptions used in the Company’s assessment represent a Level 3 measurement because they are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value. The assumptions used in the impairment analysis are inherently subject to uncertainty and, therefore, changes in these assumptions could have a significant impact on the concluded fair value.
Amortization expense for intangible assets for the years ended December 31, 2025, 2024 and 2023 were as follows:
| For the Years Ended December 31, | ||||||||||||
| 2025 | 2024 | 2023 | ||||||||||
| Patents | $ | 12,000 | $ | 56,000 | $ | 84,000 | ||||||
| Licenses | 3,000 | 35,000 | 7,000 | |||||||||
| Acquired product rights | 16,962,000 | 11,669,000 | 9,937,000 | |||||||||
| Customer relationships | 13,000 | 22,000 | 54,000 | |||||||||
| Trade name | 1,000 | 1,000 | ||||||||||
| $ | 16,991,000 | $ | 11,783,000 | $ | 10,082,000 | |||||||
Estimated future amortization expense for the Company’s intangible assets at December 31, 2025 is as follows:
| Years ending December 31, | ||||
| 2026 | $ | 16,712,000 | ||
| 2027 | 16,421,000 | |||
| 2028 | 16,014,000 | |||
| 2029 | 16,212,000 | |||
| 2030 | 15,188,000 | |||
| Thereafter | 94,299,000 | |||
| $ | 174,846,000 | |||
In connection with the license agreement with Novaliq, the Company recognized a commercial milestone of $7,000,000 related to sales of VEVYE during 2025. In connection with an asset purchase agreement between Novartis and the Company, the Company recognized a $37,000,000 milestone payment during 2024 following the release of the first commercially available batch of TRIESENCE. These milestone and upfront payments were recognized as an increase in the amount of intangible assets for acquired product rights.
There were no changes in the carrying value of the Company’s goodwill during the years ended December 31, 2025 and 2024.
Want the next HARROW, INC. goodwill & intangibles disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment HARROW, INC.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 2, 2026 | Showing above |
| 2024 | Mar 27, 2025 | |
| 2023 | Mar 19, 2024 | |
| 2022 | Mar 23, 2023 | |
| 2021 | Mar 10, 2022 | |
| 2020 | Mar 8, 2021 | |
| 2019 | Mar 13, 2020 | |
| 2018 | Mar 12, 2019 | |
| 2017 | Mar 8, 2018 | |
| 2016 | Mar 21, 2017 | |
| 2015 | Mar 23, 2016 | |
About Goodwill & Intangibles Disclosures
Goodwill and intangible asset disclosures reveal the premium paid in acquisitions and how management assesses whether that premium retains its value. Since goodwill is no longer amortized under US GAAP, the annual impairment test is the only mechanism that adjusts carrying values downward — making the assumptions behind that test critically important for investors.
Key signals: a history of goodwill impairments suggests management consistently overpays for acquisitions. Watch the gap between reporting unit fair value and carrying amount — when fair value exceeds carrying amount by less than 10-20%, a small decline in business performance could trigger a write-down. For finite-lived intangibles, examine useful life assumptions across customer relationships, technology, and trade names; aggressive estimates inflate near-term earnings. Compare total intangibles-to-total-assets ratios against peers to assess acquisition dependency. Rising goodwill as a percentage of equity can signal balance sheet fragility.